Business Context and Reporting Period
Company: Akebia Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 8, 2015
Event: Regulation FD Disclosure regarding clinical trial results.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the announcement of results from a Phase 2 study of the company's drug candidate, vadadustat (formerly AKB-6548). The study focused on dialysis patients suffering from anemia related to chronic kidney disease.
Guidance, Outlook, and Management Commentary
- Management Action: The Company issued a press release and conducted a conference call/webcast on September 8, 2015, to discuss the study results.
- Exhibits: The press release (Exhibit 99.1) and presentation materials (Exhibit 99.2) are attached to this report.
- Legal Note: The information contained in this Item is not deemed "filed" for any purpose and shall not be incorporated by reference in any other filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific clinical data and statistical outcomes of the Phase 2 vadadustat study.
- Examine the presentation materials (Exhibit 99.2) for management's interpretation of the results and potential next steps.
- Verify the regulatory implications of the Phase 2 results for the development timeline of vadadustat.